{
    "clinical_study": {
        "@rank": "60575", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with\n      selected advanced tumors characterized by wild-type TP53."
        }, 
        "brief_title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid and Hematological TP53wt Tumors", 
        "condition_browse": {
            "mesh_term": "Li-Fraumeni Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with a TP53wt locally advanced or metastatic solid malignancy and with\n             measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1\n             criteria.\n\n          -  Patients with the TP53wt hematological tumors (AML, ALL, HR-MDS) who have failed\n             prior therapies or who are considered inappropriate candidates for standard induction\n             therapy.\n\n        Other protocol-defined inclusion criteria may apply\n\n        Exclusion Criteria:\n\n          -  Prior treatment with compounds with the same mode of action\n\n          -  Subjects with significant or uncontrolled cardiovascular disease\n\n          -  History of thromboembolic or cerebrovascular events within the last 6 months,\n             including transient ischemic attack, cerebrovascular accident, deep vein thrombosis,\n             or pulmonary embolism\n\n          -  Previous and concomitant therapy that precludes enrollment, as defined in the\n             protocol\n\n          -  Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or\n             Hepatitis C infection\n\n          -  Patients who have undergone major surgery within the 2 weeks prior to starting study\n             treatment or who have not fully recovered from previous surgery\n\n          -  Women of child-bearing potential, unless they are using highly effective methods of\n             contraception during dosing and for 2 weeks after study drug discontinuation\n\n          -  Pregnant or nursing women\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143635", 
            "org_study_id": "CHDM201X2101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A", 
                "Arm B"
            ], 
            "intervention_name": "HDM201", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "HDM201,TP53wt, p53, MDM2, HDM2, advanced tumors, BLRM (Bayesian logistic regression model)", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "akomn@mskcc.org", 
                    "last_name": "Nana Akom", 
                    "phone": "646-888-4426"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Onc. Dep"
                }, 
                "investigator": {
                    "last_name": "David Hyman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "state": "Taiwan ROC", 
                        "zip": "100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Japan", 
                "Netherlands", 
                "Singapore", 
                "Spain", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: National Agency for the Safety of Medicine and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices (BfArM)", 
                "The Netherlands: Medicines Evaluation Board (MEB)", 
                "Spain: Medicines and Health Products Agency (AEMPS)", 
                "Singapore: Health Sciences Authority (HSA)", 
                "Taiwan: Center for Drug Evaluation", 
                "Japan: Pharmaceuticals and Medical Devices Agency (PMDA)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DLTs in the first cycle of treatment.", 
            "measure": "Incidence of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients with AEs as a measure of Safety and tolerability of HDM201 single agent.", 
                "measure": "Number of patients with adverse events  (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "For the duration of treatment, an average of 16 weeks"
            }, 
            {
                "measure": "Pharmacokinetics (PK) parameters of HDM201", 
                "safety_issue": "No", 
                "time_frame": "Up to 42 days"
            }, 
            {
                "measure": "Changes from baseline of Pharmacodynamics markers", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 28 days"
            }, 
            {
                "description": "end of treatment = 1 year", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks (for solid tumors), every cycle (for hematological tumors) until end of treatment"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}